Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Expression of precipitating factors of pruritus found in humans in an imiquimod-induced psoriasis mouse model.

Oishi N, Iwata H, Kambe N, Kobayashi N, Fujimoto K, Sato H, Hisaka A, Ueno K, Yamaura K.

Heliyon. 2019 Jun 20;5(6):e01981. doi: 10.1016/j.heliyon.2019.e01981. eCollection 2019 Jun.

2.

A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain.

Uzu M, Nonaka M, Miyano K, Sato H, Kurebayashi N, Yanagihara K, Sakurai T, Hisaka A, Uezono Y.

J Pharmacol Sci. 2019 May;140(1):109-112. doi: 10.1016/j.jphs.2019.04.005. Epub 2019 May 4.

3.

Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.

Sato H, Uzu M, Kashiba T, Fujiwara T, Hatakeyama H, Ueno K, Hisaka A.

Eur J Pharmacol. 2019 Mar 15;847:143-157. doi: 10.1016/j.ejphar.2019.01.040. Epub 2019 Jan 26.

PMID:
30689992
4.

A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression.

Ishida T, Tokuda K, Hisaka A, Honma M, Kijima S, Takatoku H, Iwatsubo T, Moritoyo T, Suzuki H; Alzheimer's Disease Neuroimaging Initiative.

Clin Pharmacol Ther. 2019 Feb;105(2):436-447. doi: 10.1002/cpt.1166. Epub 2018 Aug 20.

5.

Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Yoshioka H, Sato H, Hatakeyama H, Hisaka A.

Blood Adv. 2018 May 22;2(10):1066-1075. doi: 10.1182/bloodadvances.2017013805.

6.

Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.

Hatakeyama H, Fujiwara T, Sato H, Terui A, Hisaka A.

Biol Pharm Bull. 2018;41(4):619-627. doi: 10.1248/bpb.b17-00992.

7.

Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics.

Sato M, Toshimoto K, Tomaru A, Yoshikado T, Tanaka Y, Hisaka A, Lee W, Sugiyama Y.

Drug Metab Dispos. 2018 May;46(5):740-748. doi: 10.1124/dmd.117.078972. Epub 2018 Feb 23.

PMID:
29475833
8.

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Sekine Y, Shimada M, Satake S, Okubo M, Hisaka A, Hara T, Honjo M, Aihara M.

J Ocul Pharmacol Ther. 2018 Apr;34(3):280-286. doi: 10.1089/jop.2017.0091. Epub 2018 Jan 11.

PMID:
29323612
9.

Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.

Yamamoto T, Furihata K, Hisaka A, Moritoyo T, Ogoe K, Kusayama S, Motohashi K, Mori A, Iwatsubo T, Suzuki H.

J Clin Pharmacol. 2017 Nov;57(11):1491-1499. doi: 10.1002/jcph.956. Epub 2017 Jul 5.

PMID:
28679023
10.

Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells.

Uzu M, Sato H, Shimizu A, Shibata Y, Ueno K, Hisaka A.

J Pharmacol Sci. 2017 Jun;134(2):101-107. doi: 10.1016/j.jphs.2017.05.005. Epub 2017 May 27.

11.

Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models.

Ando H, Hatakeyama H, Sato H, Hisaka A, Suzuki H.

J Pharm Sci. 2017 Sep;106(9):2771-2779. doi: 10.1016/j.xphs.2017.04.065. Epub 2017 May 4.

PMID:
28479352
12.

Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.

Takaki J, Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H.

Biol Pharm Bull. 2016 May 1;39(5):863-8. doi: 10.1248/bpb.b16-00014. Epub 2016 Mar 4.

13.

[Roles of modeling and simulation in regulatory science].

Hisaka A.

Nihon Yakurigaku Zasshi. 2015 Oct;146(4):180-4. doi: 10.1254/fpj.146.180. Japanese. No abstract available.

PMID:
26656960
14.

Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport.

Ito N, Ito K, Ikebuchi Y, Toyoda Y, Takada T, Hisaka A, Oka A, Suzuki H.

Pharm Res. 2015 Aug;32(8):2527-37. doi: 10.1007/s11095-015-1641-2. Epub 2015 Feb 19.

PMID:
25690342
15.

A new physiologically based pharmacokinetic model for the prediction of gastrointestinal drug absorption: translocation model.

Ando H, Hisaka A, Suzuki H.

Drug Metab Dispos. 2015 Apr;43(4):590-602. doi: 10.1124/dmd.114.060038. Epub 2015 Jan 23.

PMID:
25616403
16.

Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.

Shirota K, Kaneko M, Sasaki M, Minato K, Fujikata A, Ohta S, Hisaka A, Suzuki H.

Drug Metab Dispos. 2015 Feb;43(2):217-26. doi: 10.1124/dmd.114.060046. Epub 2014 Nov 24.

PMID:
25422274
17.

Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy.

Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H.

Int J Clin Pharm. 2014 Dec;36(6):1134-7. doi: 10.1007/s11096-014-0022-y. Epub 2014 Oct 7.

PMID:
25288146
18.

Organic cation transporter/solute carrier family 22a is involved in drug transfer into milk in mice.

Ito N, Ito K, Ikebuchi Y, Kito T, Miyata H, Toyoda Y, Takada T, Hisaka A, Honma M, Oka A, Kusuhara H, Suzuki H.

J Pharm Sci. 2014 Oct;103(10):3342-8. doi: 10.1002/jps.24138. Epub 2014 Aug 29.

PMID:
25175747
19.

Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions.

Hisaka A, Nakamura M, Tsukihashi A, Koh S, Suzuki H.

Drug Metab Dispos. 2014 Oct;42(10):1640-5. doi: 10.1124/dmd.114.059147. Epub 2014 Jul 24.

PMID:
25061161
20.

Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.

Yamashita F, Sasa Y, Yoshida S, Hisaka A, Asai Y, Kitano H, Hashida M, Suzuki H.

PLoS One. 2013 Sep 24;8(9):e70330. doi: 10.1371/journal.pone.0070330. eCollection 2013.

21.

Contribution of protein binding, lipid partitioning, and asymmetrical transport to drug transfer into milk in mouse versus human.

Ito N, Ito K, Koshimichi H, Hisaka A, Honma M, Igarashi T, Suzuki H.

Pharm Res. 2013 Sep;30(9):2410-22. doi: 10.1007/s11095-013-1085-5. Epub 2013 May 31.

PMID:
23722410
22.

High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.

Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K.

J Antimicrob Chemother. 2013 Sep;68(9):2128-33. doi: 10.1093/jac/dkt133. Epub 2013 Apr 26.

PMID:
23625638
23.

Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.

Kudo T, Hisaka A, Sugiyama Y, Ito K.

Drug Metab Dispos. 2013 Feb;41(2):362-71. doi: 10.1124/dmd.112.049460. Epub 2012 Nov 8.

PMID:
23139378
24.

Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function.

Yamamoto T, Terakawa H, Hisaka A, Suzuki H.

J Pharm Sci. 2012 Aug;101(8):2968-75. doi: 10.1002/jps.23183. Epub 2012 May 8.

PMID:
22570265
25.

Analysis and prediction of drug transfer into human milk taking into consideration secretion and reuptake clearances across the mammary epithelia.

Koshimichi H, Ito K, Hisaka A, Honma M, Suzuki H.

Drug Metab Dispos. 2011 Dec;39(12):2370-80. doi: 10.1124/dmd.111.040972. Epub 2011 Sep 22.

PMID:
21940904
26.

Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.

Yamamoto T, Yasuno N, Katada S, Hisaka A, Hanafusa N, Noiri E, Yahagi N, Fujita T, Suzuki H.

Antimicrob Agents Chemother. 2011 Dec;55(12):5804-12. doi: 10.1128/AAC.01758-10. Epub 2011 Sep 12.

27.

Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide.

Masuo Y, Ito K, Yamamoto T, Hisaka A, Honma M, Suzuki H.

Drug Metab Dispos. 2010 Oct;38(10):1828-35. doi: 10.1124/dmd.110.034231. Epub 2010 Jun 25.

PMID:
20581094
28.

Theoretical considerations on quantitative prediction of drug-drug interactions.

Hisaka A, Ohno Y, Yamamoto T, Suzuki H.

Drug Metab Pharmacokinet. 2010;25(1):48-61. Review.

29.

Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.

Hisaka A, Ohno Y, Yamamoto T, Suzuki H.

Pharmacol Ther. 2010 Feb;125(2):230-48. doi: 10.1016/j.pharmthera.2009.10.011. Epub 2009 Dec 3. Review.

PMID:
19951720
30.
31.

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Ohno Y, Hisaka A, Ueno M, Suzuki H.

Clin Pharmacokinet. 2008;47(10):669-80.

PMID:
18783297
33.
34.

The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y.

Drug Metab Pharmacokinet. 2003;18(6):365-72.

36.

6-Carboxy-5,7-diarylcyclopenteno[1,2-b]pyridine derivatives: a novel class of endothelin receptor antagonists.

Niiyama K, Mase T, Takahashi H, Naya A, Katsuki K, Nagase T, Ito S, Hayama T, Hisaka A, Ozaki S, Ihara M, Yano M, Fukuroda T, Noguchi K, Nishikibe M, Ishikawa K.

Bioorg Med Chem. 2002 Aug;10(8):2461-70.

PMID:
12057635
37.

Problems of mixed boundary conditions for convection-dispersion models in the analysis of local pharmacokinetics.

Hisaka A, Sugiyama Y.

J Pharm Sci. 2000 Dec;89(12):1587-8. No abstract available.

PMID:
11042606
39.

Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats.

Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y.

J Pharmacol Exp Ther. 1999 Sep;290(3):1107-15.

PMID:
10454484
40.
42.

Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane.

Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y.

J Pharmacol Exp Ther. 1999 Feb;288(2):575-81.

PMID:
9918561
43.

Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats.

Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y.

J Pharmacol Exp Ther. 1999 Feb;288(2):568-74.

PMID:
9918560
44.

Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data.

Iwatsubo T, Hisaka A, Suzuki H, Sugiyama Y.

J Pharmacol Exp Ther. 1998 Jul;286(1):122-7.

PMID:
9655850
45.

Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123.

Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y.

Am J Physiol. 1997 May;272(5 Pt 1):G979-86.

PMID:
9176204
46.

The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.

Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y.

J Pharmacol Exp Ther. 1996 Aug;278(2):607-13.

PMID:
8768710
47.

Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.

Nakamura T, Hisaka A, Sawasaki Y, Suzuki Y, Fukami T, Ishikawa K, Yano M, Sugiyama Y.

J Pharmacol Exp Ther. 1996 Aug;278(2):564-72.

PMID:
8768705
48.

Cyclic pentapeptide endothelin A receptor antagonists with attenuated in vivo clearance.

Fukami T, Niiyama K, Amano Y, Hisaka A, Fujino N, Sawasaki Y, Ihara M, Ishikawa K.

Chem Pharm Bull (Tokyo). 1996 Mar;44(3):609-14.

PMID:
8882459
49.

Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure.

Konishi K, Suzuki H, Saruta T, Hayashi M, Deguchi N, Tazaki H, Hisaka A.

Antimicrob Agents Chemother. 1991 Aug;35(8):1616-20.

50.

Absorption of a novel prodrug of L-dopa, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355). In vitro and in situ studies.

Hisaka A, Kasamatsu S, Takenaga N, Ohtawa M.

Drug Metab Dispos. 1990 Sep-Oct;18(5):621-5.

PMID:
1981710

Supplemental Content

Loading ...
Support Center